XLO — XILIO THERAPEUTICS INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 27 SEC-registered investment managers reported holding XLO (XILIO THERAPEUTICS INC) in their latest 13F filings, with a combined reported value of $32.89M across 3.43M shares. That is +9.2% by share count (+219.33K shares) versus the previous quarter, while reported value moved +24.4%. Ownership is concentrated: the five largest holders account for 74.4% of reported value and the top ten for 92.3%.
Compared with the prior quarter, 12 opened new positions, 4 added to existing stakes, 4 trimmed, 9 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of XILIO THERAPEUTICS INC (XLO) include Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., ORBIMED ADVISORS LLC, ranked by reported 13F value among the 94 institutional holders on this page.
XLO is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 17 | 1.37M | $12.42M | -0.8% |
| Q2 2026 | 27 | 3.43M | $32.89M | +9.2% |
| Q1 2026 | 24 | 2.62M | $22.03M | -92.3% |
| Q4 2025 | 37 | 39.73M | $25.43M | +13.9% |
| Q3 2025 | 35 | 20.58M | $17.37M | -1.6% |
| Q2 2025 | 34 | 22.32M | $15.18M | -1.1% |
| Q1 2025 | 35 | 21.10M | $15.29M | -1.4% |
| Q4 2024 | 34 | 24.38M | $23.27M | -1.4% |
Over the 8 quarters shown, institutional share counts decreased 94% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q1 2026 (-92.3%).
Top Institutional Holders (Q3 2026) — 17 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 650.39K | $5.89M | 0.40% | Hold | |
| 198.18K | $1.79M | 0.00% | Add | |
| 189.09K | $1.71M | 1.31% | Reduce | |
| 105.98K | $959.14K | 0.12% | Hold | |
| 63.55K | $575.15K | 0.00% | Reduce | |
| 53.67K | $485.75K | 0.00% | Reduce | |
| 41.45K | $375.14K | 0.00% | Add | |
| 28.19K | $255.15K | 0.00% | Add | |
| 13.31K | $120.47K | 0.00% | Hold | |
| 12.45K | $112.00K | 0.00% | New | |
| 10.91K | $98.72K | 0.00% | Add | |
| 3.36K | $30.40K | 0.00% | New | |
| 714 | $6.46K | 0.00% | Hold | |
| 544 | $4.92K | 0.00% | Add | |
| 59 | $534 | 0.00% | Hold | |
| 58 | $524 | 0.00% | Add | |
| 1 | $9 | 0.00% | New |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 25 funds
Q1 2026 — 24 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 664.02K | $5.58M | 0.50% | Reduce | |
| 650.39K | $5.47M | 0.26% | Reduce | |
| 422.50K | $3.55M | 0.09% | Reduce | |
| 152.46K | $1.28M | 0.18% | Reduce | |
| 123.66K | $1.04M | 0.00% | New | |
| 112.13K | $943.00K | 0.07% | New | |
| 105.98K | $891.31K | 0.26% | Reduce | |
| 64.16K | $539.60K | 0.32% | Reduce | |
| 57.49K | $483.52K | 0.00% | Reduce | |
| 49.57K | $416.85K | 0.00% | Reduce | |
| 47.70K | $401.12K | 1.31% | Reduce | |
| 37.20K | $312.85K | 0.00% | Reduce | |
| 36.56K | $307.45K | 0.00% | Reduce | |
| 28.48K | $239.47K | 0.00% | New | |
| 16.95K | $143.00K | 0.01% | Reduce | |
| 14.29K | $120.14K | 0.07% | Reduce | |
| 13.80K | $116.06K | 0.01% | Reduce | |
| 13.31K | $111.95K | 0.00% | Reduce | |
| 4.21K | $35.37K | 0.00% | New | |
| 4.04K | $33.96K | 0.00% | Add | |
| 240 | $1.98K | 0.00% | New | |
| 210 | $1.77K | 0.00% | New | |
| 91 | $1.00K | 0.00% | New | |
| 59 | $496 | 0.00% | Reduce |
Q4 2025 — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 9.11M | $5.83M | 0.30% | Hold | |
| 7.37M | $4.72M | 0.36% | Add | |
| 5.92M | $3.79M | 0.10% | New | |
| 4.00M | $2.56M | 0.01% | New | |
| 2.13M | $1.37M | 0.21% | New | |
| 2.03M | $1.30M | 0.25% | New | |
| 1.48M | $949.90K | 0.34% | Hold | |
| 1.26M | $803.64K | 0.00% | Hold | |
| 1.18M | $757.38K | 0.67% | New | |
| 1.11M | $712.68K | 0.05% | New | |
| 839.85K | $537.67K | 0.00% | Reduce | |
| 667.74K | $427.49K | 1.88% | Hold | |
| 511.82K | $327.67K | 0.00% | Hold | |
| 436.22K | $279.26K | 0.00% | New | |
| 344.42K | $220.50K | 0.00% | Add | |
| 328.97K | $210.63K | 0.00% | Hold | |
| 186.39K | $119.33K | 0.00% | Add | |
| 170.00K | $108.83K | 0.06% | New | |
| 147.97K | $95.00K | 0.01% | New | |
| 126.27K | $80.84K | 0.06% | New | |
| 66.61K | $42.64K | 0.00% | Hold | |
| 62.03K | $39.71K | 0.00% | Reduce | |
| 56.08K | $35.90K | 0.00% | Hold | |
| 42.08K | $26.94K | 0.00% | New | |
| 31.89K | $20.00K | 0.00% | Add |
Q3 2025 — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 9.11M | $7.67M | 0.43% | Hold | |
| 4.57M | $3.85M | 0.26% | Hold | |
| 1.48M | $1.25M | 0.55% | Hold | |
| 1.26M | $1.06M | 0.00% | Add | |
| 961.92K | $810.61K | 0.00% | Reduce | |
| 667.74K | $595.56K | 0.52% | Hold | |
| 511.82K | $431.31K | 0.00% | Hold | |
| 328.97K | $277.26K | 0.00% | Reduce | |
| 328.79K | $277.07K | 0.00% | Add | |
| 249.63K | $210.44K | 0.03% | Hold | |
| 204.70K | $172.50K | 0.00% | Add | |
| 198.86K | $167.58K | 0.00% | Hold | |
| 163.89K | $138.11K | 0.00% | Add | |
| 87.79K | $73.98K | 0.00% | Add | |
| 76.05K | $64.08K | 0.00% | Add | |
| 66.61K | $56.13K | 0.00% | Hold | |
| 56.08K | $47.26K | 0.00% | Hold | |
| 32.13K | $27.08K | 0.00% | New | |
| 31.00K | $26.12K | 0.00% | Hold | |
| 29.69K | $25.02K | 0.00% | New | |
| 25.00K | $21.07K | 0.00% | Hold | |
| 25.00K | $21.07K | 0.00% | Hold | |
| 24.74K | $20.00K | 0.00% | New | |
| 25.00K | $19.33K | 0.00% | Hold | |
| 18.76K | $15.81K | 0.00% | Hold |
Q2 2025 — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 9.11M | $6.19M | 0.48% | Hold | |
| 4.57M | $3.10M | 0.39% | Hold | |
| 1.48M | $1.01M | 0.47% | Hold | |
| 1.44M | $982.00K | 0.00% | Add | |
| 1.33M | $906.31K | 0.03% | New | |
| 1.15M | $782.70K | 0.00% | Add | |
| 667.74K | $454.00K | 0.49% | Hold | |
| 511.82K | $347.99K | 0.00% | Reduce | |
| 369.66K | $251.35K | 0.00% | Reduce | |
| 249.63K | $169.75K | 0.03% | Hold | |
| 239.97K | $163.18K | 0.00% | Add | |
| 235.46K | $160.09K | 0.00% | New | |
| 198.86K | $135.20K | 0.00% | Reduce | |
| 164.20K | $111.64K | 0.00% | Reduce | |
| 142.34K | $96.78K | 0.00% | Reduce | |
| 78.03K | $53.05K | 0.00% | Reduce | |
| 66.61K | $45.29K | 0.00% | Hold | |
| 56.08K | $38.13K | 0.00% | Reduce | |
| 43.39K | $29.50K | 0.00% | Hold | |
| 34.72K | $23.61K | 0.00% | New | |
| 31.00K | $21.08K | 0.00% | New | |
| 25.00K | $17.50K | 0.00% | Reduce | |
| 25.00K | $17.00K | 0.00% | Reduce | |
| 25.00K | $17.00K | 0.00% | Hold | |
| 18.76K | $12.76K | 0.00% | Reduce |
New Positions (Q2 2026)
- ORBIMED ADVISORS LLC 592.30K sh · $5.67M
- ADAGE CAPITAL PARTNERS GP, L.L.C. 111.54K sh · $1.07M
- GEODE CAPITAL MANAGEMENT, LLC 39.05K sh · $374.17K
- Citadel Advisors 25.95K sh · $248.60K
- BRIDGEWAY CAPITAL MANAGEMENT, LLC 17.54K sh · $168.07K
- Two Sigma Investments 14.54K sh · $139.33K
- PRELUDE CAPITAL MANAGEMENT, LLC 11.60K sh · $111.13K
- BlackRock Inc 8.76K sh · $83.89K
- Steward Partners Investment Advisory, LLC 714 sh · $6.84K
- SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ 321 sh · $3.08K
- BARCLAYS PLC 115 sh · $1.10K
- JONES FINANCIAL COMPANIES LLLP 29 sh · $262
Fully Exited (vs previous quarter)
- Caligan Partners LP sold 112.13K sh · $943.00K
- AJU IB Investment Co., Ltd. sold 47.70K sh · $401.12K
- Fidelity Management & Research (FMR) sold 36.56K sh · $307.45K
- Ghisallo Capital Management LLC sold 13.80K sh · $116.06K
- STATE STREET CORP sold 13.31K sh · $111.95K
- CWM, LLC sold 4.21K sh · $35.37K
- JPMorgan Chase & Co sold 240 sh · $1.98K
- Vanguard Global Advisers, LLC sold 210 sh · $1.77K
- ROYAL BANK OF CANADA sold 91 sh · $1.00K
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 650.39K | 650.39K | 650.39K | 9.11M | 9.11M | 9.11M | 9.11M | 9.11M | — | — | — | — | — | — | — | — | — | — | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 198.18K | 178.52K | 123.66K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stonepine Capital Management, LLC | 189.09K | 225.99K | 64.16K | 126.27K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Merck & Co., Inc. | 105.98K | 105.98K | 105.98K | 1.48M | 1.48M | 1.48M | 1.48M | 1.48M | — | — | — | — | — | — | — | — | — | — | — | — |
| Renaissance Technologies | 63.55K | 64.15K | 49.57K | 344.42K | 204.70K | 164.20K | 177.70K | 296.62K | 266.30K | 295.00K | 249.45K | 209.70K | 20.70K | 20.30K | 18.80K | 37.10K | 28.50K | 75.30K | — | — |
| Morgan Stanley | 53.67K | 56.95K | 57.49K | 839.85K | 961.92K | 1.44M | 1.16M | 1.00M | 1.52M | 1.11M | 221.91K | 127.27K | 26.27K | 27.02K | 30.54K | 25.61K | 6.84K | 7.04K | 2.10K | 1.04K |
| Geode Capital Management | 41.45K | 39.05K | 37.20K | 328.97K | 328.97K | 369.66K | 379.02K | 358.42K | 338.19K | 182.85K | 84.83K | 84.83K | 84.83K | 84.73K | 84.73K | 84.73K | 83.59K | 83.59K | 141.71K | 134.19K |
| VANGUARD FIDUCIARY TRUST CO | 28.19K | 22.59K | 28.48K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| STATE STREET CORP | 13.31K | — | 13.31K | 186.39K | 163.89K | 43.39K | 43.39K | 43.39K | 43.39K | 43.39K | 15.69K | 15.69K | 15.69K | — | — | — | — | — | — | — |
| HRT FINANCIAL LP | 12.45K | — | — | 31.89K | 24.74K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BlackRock Inc | 10.91K | 8.76K | — | 2.04K | 2.04K | 2.04K | 74.70K | 76.09K | 75.62K | — | — | — | — | — | — | — | — | — | — | — |
| Vanguard Global Advisers, LLC | 3.36K | — | 210 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Steward Partners Investment Advisory, LLC | 714 | 714 | — | — | — | — | 20.00K | 20.00K | 20.00K | — | — | — | — | — | — | — | — | — | — | — |
| UBS Group AG | 544 | 14 | 4.04K | 203 | 13.65K | 239.97K | 163.10K | 249.40K | 15.73K | 201 | 201 | 201 | 201 | 201 | 201 | 201 | 201 | 2.81K | 964 | 3.98K |
| Key FInancial Inc | 59 | 59 | 59 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | 830 | — | — | — | — | — | — | — |
| JONES FINANCIAL COMPANIES LLLP | 58 | 29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Citigroup Inc | 1 | — | — | — | 258 | — | — | — | — | — | — | — | — | — | — | — | — | 67 | 323 | 2.19K |
| Bain Capital Life Sciences Investors, LLC | — | 664.02K | 664.02K | 7.37M | 4.57M | 4.57M | 4.57M | 4.57M | 4.57M | 3.79M | 2.81M | 2.81M | 2.81M | — | — | — | — | — | — | — |
| Atlas Venture Life Science Advisors, LLC | — | — | — | — | — | — | — | — | — | — | 992.91K | 2.76M | 2.76M | — | — | — | — | — | — | — |
| ORBIMED ADVISORS LLC | — | 592.30K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold XLO?
As of 2026-Q2, 27 institutional funds reported holding XLO (XILIO THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $32.89M.
How many shares of XLO do institutions own?
13F filers reported 3.43M shares of XLO, worth $32.89M in aggregate at the end of 2026-Q2.
Is institutional ownership of XLO rising or falling?
Share counts moved +9.2% versus the prior quarter — accumulation.
Who are the top institutional holders of XLO?
The largest 13F holders are Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., ORBIMED ADVISORS LLC, Frazier Life Sciences Management, L.P., Rock Springs Capital Management LP; the top 25 are ranked at the top of this page.
Who are the major shareholders of XILIO THERAPEUTICS INC?
The major shareholders of XILIO THERAPEUTICS INC (XLO) by reported 13F value are Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., ORBIMED ADVISORS LLC, Frazier Life Sciences Management, L.P., Rock Springs Capital Management LP, among 94 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.